Aktis Oncology (AKTS)
Market Price (7/6/2026): $31.8 | Market Cap: $1.5 BilSector: Health Care | Industry: Biotechnology
Aktis Oncology (AKTS)
Market Price (7/6/2026): $31.8Market Cap: $1.5 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -34% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. | Trading close to highsDist 52W High is -1.5%, Dist 3Y High is -1.5% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.57 | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -74 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -988% Expensive valuation multiplesP/SPrice/Sales ratio is 207x Stock price has recently run up significantly6M Rtn6 month market price return is 9223372036854775807%, 12M Rtn12 month market price return is 9223372036854775807% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 86% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -933%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1069% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 9223372036854775807% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.2% High stock price volatilityVol 12M is 280% Key risksAKTS key risks include [1] its heavy dependence on a limited, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -34% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. |
| Trading close to highsDist 52W High is -1.5%, Dist 3Y High is -1.5% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.57 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -74 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -988% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 207x |
| Stock price has recently run up significantly6M Rtn6 month market price return is 9223372036854775807%, 12M Rtn12 month market price return is 9223372036854775807% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 86% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -933%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1069% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 9223372036854775807% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.2% |
| High stock price volatilityVol 12M is 280% |
| Key risksAKTS key risks include [1] its heavy dependence on a limited, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/1/2026
Aktis Oncology (AKTS) stock has gained about 80% since 3/31/2026 because of the following key factors:
1. Significant advancements in its clinical pipeline, particularly for AKY-2519, bolstered investor confidence. Aktis Oncology initiated a Phase 1b clinical trial for AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC) in early fiscal Q2 2026 (May 4, 2026). This was followed by the presentation of robust first-in-human clinical imaging and dosimetry data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29 – June 2, 2026), which demonstrated strong tumor uptake and limited normal tissue exposures. These developments followed the FDA's clearance of Investigational New Drug (IND) applications for AKY-2519 in late fiscal Q1 2026 (March 30, 2026).
2. Aktis Oncology demonstrated a strong financial position, providing a long cash runway. Despite reporting a wider-than-expected net loss per share of -$0.38 for fiscal Q1 2026, the company highlighted cash, cash equivalents, and marketable securities totaling $538.5 million as of March 31, 2026. This substantial liquidity is expected to fund operations into 2029, reducing immediate capital concerns for the pre-revenue clinical-stage company.
Show more
Aktis Oncology (AKTS) stock has gained about 80% since 3/31/2026 because of the following key factors:
1. Significant advancements in its clinical pipeline, particularly for AKY-2519, bolstered investor confidence. Aktis Oncology initiated a Phase 1b clinical trial for AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC) in early fiscal Q2 2026 (May 4, 2026). This was followed by the presentation of robust first-in-human clinical imaging and dosimetry data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29 – June 2, 2026), which demonstrated strong tumor uptake and limited normal tissue exposures. These developments followed the FDA's clearance of Investigational New Drug (IND) applications for AKY-2519 in late fiscal Q1 2026 (March 30, 2026).
2. Aktis Oncology demonstrated a strong financial position, providing a long cash runway. Despite reporting a wider-than-expected net loss per share of -$0.38 for fiscal Q1 2026, the company highlighted cash, cash equivalents, and marketable securities totaling $538.5 million as of March 31, 2026. This substantial liquidity is expected to fund operations into 2029, reducing immediate capital concerns for the pre-revenue clinical-stage company.
Show more
Updated on 7/1/2026
Aktis Oncology (AKTS) stock has gained about 80% since 3/31/2026 because of the following key factors:
1. Significant advancements in its clinical pipeline, particularly for AKY-2519, bolstered investor confidence. Aktis Oncology initiated a Phase 1b clinical trial for AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC) in early fiscal Q2 2026 (May 4, 2026). This was followed by the presentation of robust first-in-human clinical imaging and dosimetry data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29 – June 2, 2026), which demonstrated strong tumor uptake and limited normal tissue exposures. These developments followed the FDA's clearance of Investigational New Drug (IND) applications for AKY-2519 in late fiscal Q1 2026 (March 30, 2026).
2. Aktis Oncology demonstrated a strong financial position, providing a long cash runway. Despite reporting a wider-than-expected net loss per share of -$0.38 for fiscal Q1 2026, the company highlighted cash, cash equivalents, and marketable securities totaling $538.5 million as of March 31, 2026. This substantial liquidity is expected to fund operations into 2029, reducing immediate capital concerns for the pre-revenue clinical-stage company.
3. Inclusion in the S&P Global BMI Index and positive analyst coverage enhanced market visibility and sentiment. On June 21, 2026, Aktis Oncology was added to the S&P Global BMI Index, a move often associated with increased passive fund buying and a broadened investor base. This event contributed to the stock surging nearly 9% on June 22, 2026, and gaining an additional nearly 3% on June 23, 2026. Furthermore, H.C. Wainwright reiterated a "Buy" rating and increased its price target from $33 to $35, citing strong early clinical data.
4. A favorable macroeconomic backdrop, characterized by significant M&A activity in the biotech sector, contributed to positive investor sentiment. Renewed M&A enthusiasm within the broader biotech industry during fiscal Q2 2026 created tailwinds for oncology companies. Notable examples include GSK's $10.6 billion acquisition of Nuvalent and AbbVie's approximately $11 billion deal to acquire Apogee Therapeutics, which underscored a positive environment for innovation in cancer treatment.
Show less
Aktis Oncology (AKTS) stock has gained about 80% since 3/31/2026 because of the following key factors:
1. Significant advancements in its clinical pipeline, particularly for AKY-2519, bolstered investor confidence. Aktis Oncology initiated a Phase 1b clinical trial for AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC) in early fiscal Q2 2026 (May 4, 2026). This was followed by the presentation of robust first-in-human clinical imaging and dosimetry data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29 – June 2, 2026), which demonstrated strong tumor uptake and limited normal tissue exposures. These developments followed the FDA's clearance of Investigational New Drug (IND) applications for AKY-2519 in late fiscal Q1 2026 (March 30, 2026).
2. Aktis Oncology demonstrated a strong financial position, providing a long cash runway. Despite reporting a wider-than-expected net loss per share of -$0.38 for fiscal Q1 2026, the company highlighted cash, cash equivalents, and marketable securities totaling $538.5 million as of March 31, 2026. This substantial liquidity is expected to fund operations into 2029, reducing immediate capital concerns for the pre-revenue clinical-stage company.
3. Inclusion in the S&P Global BMI Index and positive analyst coverage enhanced market visibility and sentiment. On June 21, 2026, Aktis Oncology was added to the S&P Global BMI Index, a move often associated with increased passive fund buying and a broadened investor base. This event contributed to the stock surging nearly 9% on June 22, 2026, and gaining an additional nearly 3% on June 23, 2026. Furthermore, H.C. Wainwright reiterated a "Buy" rating and increased its price target from $33 to $35, citing strong early clinical data.
4. A favorable macroeconomic backdrop, characterized by significant M&A activity in the biotech sector, contributed to positive investor sentiment. Renewed M&A enthusiasm within the broader biotech industry during fiscal Q2 2026 created tailwinds for oncology companies. Notable examples include GSK's $10.6 billion acquisition of Nuvalent and AbbVie's approximately $11 billion deal to acquire Apogee Therapeutics, which underscored a positive environment for innovation in cancer treatment.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 77.5% change in AKTS stock from 3/31/2026 to 7/5/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312026 | 7052026 | Change |
|---|---|---|---|
| Stock Price ($) | 17.89 | 31.76 | 77.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | � | 0.0% |
| P/S Multiple | 221.1 | � | 0.0% |
| Shares Outstanding (Mil) | 53 | 35 | 50.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2026 to 7/5/2026| Return | Correlation | |
|---|---|---|
| AKTS | 77.5% | |
| Market (SPY) | 14.5% | 18.3% |
| Sector (XLV) | 11.7% | 17.6% |
Fundamental Drivers
nullnull
Market Drivers
12/31/2025 to 7/5/2026| Return | Correlation | |
|---|---|---|
| AKTS | ∞% | |
| Market (SPY) | 9.5% | 36.5% |
| Sector (XLV) | 6.2% | 33.2% |
Fundamental Drivers
nullnull
Market Drivers
6/30/2025 to 7/5/2026| Return | Correlation | |
|---|---|---|
| AKTS | ∞% | |
| Market (SPY) | 21.6% | � |
| Sector (XLV) | 23.1% | � |
Fundamental Drivers
nullnull
Market Drivers
6/30/2023 to 7/5/2026| Return | Correlation | |
|---|---|---|
| AKTS | 898.7% | |
| Market (SPY) | 74.0% | � |
| Sector (XLV) | 29.1% | � |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AKTS Return | -45% | -58% | -70% | -99% | -100% | ∞% | -100% |
| Peers Return | 29% | 34% | 13% | -0% | 2% | 16% | 131% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 99% |
Monthly Win Rates [3] | |||||||
| AKTS Win Rate | 25% | 50% | 50% | 25% | 33% | 50% | |
| Peers Win Rate | 45% | 60% | 40% | 53% | 55% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| AKTS Max Drawdown | -67% | -67% | -90% | -99% | -100% | -32% | |
| Peers Max Drawdown | -38% | -31% | -47% | -52% | -43% | -27% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: LNTH, ATNM, CATX, LLY, BMY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/2/2026 (YTD)
How Low Can It Go
| Event | AKTS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -100.0% | -18.8% |
| % Gain to Breakeven | ∞% | 23.1% |
| Time to Breakeven | 232 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -37.4% | -7.8% |
| % Gain to Breakeven | 59.7% | 8.5% |
| Time to Breakeven | 518 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -79.2% | -9.5% |
| % Gain to Breakeven | 381.3% | 10.5% |
| Time to Breakeven | 802 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -34.6% | -6.7% |
| % Gain to Breakeven | 53.0% | 7.1% |
| Time to Breakeven | 983 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -66.6% | -24.5% |
| % Gain to Breakeven | 199.6% | 32.4% |
| Time to Breakeven | 1177 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -49.1% | -33.7% |
| % Gain to Breakeven | 96.4% | 50.9% |
| Time to Breakeven | 30 days | 140 days |
In The Past
Aktis Oncology's stock fell null during the 2025 US Tariff Shock. Such a loss loss requires a 9.2233720368547763E17% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | AKTS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -100.0% | -18.8% |
| % Gain to Breakeven | ∞% | 23.1% |
| Time to Breakeven | 232 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -37.4% | -7.8% |
| % Gain to Breakeven | 59.7% | 8.5% |
| Time to Breakeven | 518 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -79.2% | -9.5% |
| % Gain to Breakeven | 381.3% | 10.5% |
| Time to Breakeven | 802 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -34.6% | -6.7% |
| % Gain to Breakeven | 53.0% | 7.1% |
| Time to Breakeven | 983 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -66.6% | -24.5% |
| % Gain to Breakeven | 199.6% | 32.4% |
| Time to Breakeven | 1177 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -49.1% | -33.7% |
| % Gain to Breakeven | 96.4% | 50.9% |
| Time to Breakeven | 30 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -54.3% | -19.2% |
| % Gain to Breakeven | 118.7% | 23.8% |
| Time to Breakeven | 93 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -69.8% | -12.2% |
| % Gain to Breakeven | 231.1% | 13.9% |
| Time to Breakeven | 306 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -39.6% | -6.8% |
| % Gain to Breakeven | 65.6% | 7.3% |
| Time to Breakeven | 121 days | 15 days |
In The Past
Aktis Oncology's stock fell null during the 2025 US Tariff Shock. Such a loss loss requires a 9.2233720368547763E17% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Aktis Oncology (AKTS)
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and semiconductor wafer-manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company was incorporated in 2013 and is headquartered in Huntersville, North Carolina.
AI Analysis | Feedback
- It's like Corning, but instead of making specialized glass for smartphone screens, Akoustis makes the high-performance filters essential for wireless communication in your phone and Wi-Fi.
- Think of it as a specialized TSMC or GlobalFoundries, but entirely focused on designing and manufacturing advanced radio frequency filters and MEMS for wireless devices.
- It's like the "Intel Inside" for wireless communication, creating the critical filter components that enable your smartphone, Wi-Fi, and other wireless tech to function reliably.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Here are the key risks to Aktis Oncology's business:
- Clinical Development and Regulatory Risk: As a clinical-stage oncology company, Aktis Oncology's success is heavily dependent on the successful development, clinical trials, and regulatory approval of its product candidates, such as AKY-1189 and AKY-2519. The company's lead candidate, AKY-1189, recently received FDA Fast Track designation for advanced urothelial cancer, which can accelerate development and review but does not mitigate the inherent scientific or clinical risks. Uncertainties exist regarding the progression and safety data from ongoing trials like NECTINIUM-2 Phase 1b, and the potential for its therapies to address a broad range of tumor types beyond those initially targeted remains to be fully established.
- Financial Risk and Reliance on External Funding: Aktis Oncology is currently unprofitable and is not expected to achieve profitability within the next three years, with analysts forecasting an average annual earnings decline of 25.5% over this period. The company is in an investment-heavy phase and will likely need to rely on external funding to finance its research and development activities and advance its pipeline. The ability to secure sufficient capital and manage its cash runway effectively are critical financial considerations.
- Supply Chain Risk for Alpha-Emitting Isotopes: Aktis Oncology specializes in developing radiopharmaceutical therapies that utilize alpha-emitting isotopes, such as Actinium-225. The availability and consistent supply of these specialized isotopes are crucial for the development and potential commercialization of their products. Fluctuations in the supply chain or changes in the landscape of alpha-emitting isotope production could pose a risk to the company's operations and strategy.
AI Analysis | Feedback
null
AI Analysis | Feedback
Aktis Oncology (symbol: AKTS) operates in the radiopharmaceutical market, developing targeted radiopharmaceuticals for solid tumors. The company's main product candidates include AKY-1189, which targets Nectin-4 for urothelial cancer and other Nectin-4 expressing tumors, and AKY-2519, which targets B7-H3 for prostate and lung cancers.
The addressable market for radiopharmaceuticals is projected to exceed **$26 billion globally by 2032**. The therapeutic segment of this market is estimated to reach **$25–$60 billion globally post-2030**. More broadly, the radiopharmaceutical market was valued at $6.2 billion in 2024 and is projected to reach $19.6 billion by 2034, demonstrating a compound annual growth rate (CAGR) of 12.7%.
Aktis Oncology's lead candidate, AKY-1189, targets Nectin-4, which is expressed in approximately 80% to 90% of urothelial cancers, indicating a significant addressable patient population if successful. Nectin-4 is also expressed in other high-incidence tumor types.
AI Analysis | Feedback
Aktis Oncology, Inc. (NASDAQ: AKTS) is a clinical-stage oncology company focused on developing targeted radiopharmaceuticals for solid tumors. As such, its future revenue growth over the next 2-3 years will primarily be driven by the progression of its pipeline and potential market entry of its therapeutic candidates. The key drivers are expected to be:
- Advancement and Commercialization of its Miniprotein Radioconjugate Platform and Pipeline Products: Aktis Oncology's core strategy revolves around its proprietary miniprotein radioconjugate platform, designed to deliver tumor-killing radioisotopes to targeted tumors. The successful advancement of its pipeline products, such as AKY-1189, through clinical trials, regulatory approvals, and eventual commercial launch, will be the primary driver of future revenue. AKY-1189, a Nectin-4 miniprotein radioconjugate, has already received U.S. FDA Fast Track Designation for the treatment of locally advanced or metastatic urothelial cancer, which could expedite its development and review process.
- Expansion into New Cancer Indications and Patient Populations: A central part of Aktis Oncology's mission is to expand the potential of targeted radiopharmaceuticals to broad patient populations, including those not currently addressed by existing technologies. The company aims to achieve this by developing next-generation technologies that broaden the spectrum of tumor targets for effective radiopharmaceutical delivery. Successfully expanding its therapies to new solid tumor types, such as breast, lung, colorectal, bladder, and liver cancers, will unlock significant new market opportunities and contribute to revenue growth.
- Strategic Collaborations and Partnerships: As a clinical-stage biotechnology company, strategic collaborations and partnerships are crucial for funding research and development, mitigating risks, and accelerating market access. The company has already garnered "substantial backing from Big Pharma mainstay Eli Lilly", suggesting a precedent for such alliances. Future agreements for co-development, licensing, or commercialization of its platform or pipeline assets could provide significant upfront payments, milestone achievements, and royalties, thereby contributing to its revenue streams.
AI Analysis | Feedback
null
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 44.95 |
| Mkt Cap | 4.3 |
| Rev LTM | 777 |
| Op Inc LTM | 132 |
| FCF LTM | 174 |
| FCF 3Y Avg | 356 |
| CFO LTM | 192 |
| CFO 3Y Avg | 419 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.8% |
| Rev Chg 3Y Avg | 15.4% |
| Rev Chg Q | 2.6% |
| QoQ Delta Rev Chg LTM | 0.6% |
| Op Inc Chg LTM | 48.1% |
| Op Inc Chg 3Y Avg | 21.0% |
| Op Mgn LTM | 18.8% |
| Op Mgn 3Y Avg | 27.7% |
| QoQ Delta Op Mgn LTM | 1.7% |
| CFO/Rev LTM | 26.4% |
| CFO/Rev 3Y Avg | 28.1% |
| FCF/Rev LTM | 14.4% |
| FCF/Rev 3Y Avg | 23.9% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor | 6 | 0 | 0 | 0 |
| Total | 6 | 0 | 0 | 0 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor | -64 | -0 | -0 |
| Total | -64 | -0 | -0 |
| $ Mil | 2023 | 2022 |
|---|---|---|
| Research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor | 0 | 0 |
| Total | 0 | 0 |
Price Behavior
Price Behavior
| Market Price | $31.76 | |
| Market Cap ($ Bil) | 1.5 | |
| First Trading Date | 03/13/2017 | |
| Distance from 52W High | -1.5% | |
| 50 Days | 200 Days | |
| DMA Price | $17.38 | $11.05 |
| DMA Trend | up | up |
| Distance from DMA | 82.7% | 187.5% |
| 3M | 1YR | |
| Volatility | 71.0% | � |
| Downside Capture | 53.73 | � |
| Upside Capture | 251.82 | � |
| Correlation (SPY) | 21.6% | � |
AKTS Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.76 | 0.77 | 1.17 | -0.17 | � | � |
| Up Beta | -1.90 | -0.97 | 1.05 | 1.34 | � | � |
| Down Beta | 2.38 | 0.66 | 0.31 | -2.40 | � | � |
| Up Capture | 422% | 372% | 297% | 271% | � | � |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 15 | 26 | 41 | 64 | 68 | 259 |
| Down Capture | -150% | -33% | 46% | 141% | � | � |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 6 | 15 | 22 | 53 | 57 | 316 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AKTS | |
|---|---|---|---|---|
| AKTS | -100.0% | 158.8% | -0.70 | - |
| Sector ETF (XLV) | 21.4% | 15.6% | 1.05 | 13.3% |
| Equity (SPY) | 21.7% | 12.5% | 1.29 | 26.2% |
| Gold (GLD) | 23.1% | 27.7% | 0.73 | -0.7% |
| Commodities (DBC) | 21.3% | 18.6% | 0.90 | -13.2% |
| Real Estate (VNQ) | 13.6% | 13.8% | 0.68 | 10.7% |
| Bitcoin (BTCUSD) | -42.0% | 42.7% | -1.15 | 10.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AKTS | |
|---|---|---|---|---|
| AKTS | -100.0% | 198.0% | -0.90 | - |
| Sector ETF (XLV) | 7.2% | 14.9% | 0.30 | 11.6% |
| Equity (SPY) | 13.3% | 17.1% | 0.60 | 17.0% |
| Gold (GLD) | 17.9% | 18.3% | 0.79 | 3.0% |
| Commodities (DBC) | 6.9% | 19.5% | 0.25 | 2.8% |
| Real Estate (VNQ) | 3.1% | 18.9% | 0.06 | 16.0% |
| Bitcoin (BTCUSD) | 12.2% | 53.8% | 0.41 | 4.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AKTS | |
|---|---|---|---|---|
| AKTS | -100.0% | 144.9% | -0.43 | - |
| Sector ETF (XLV) | 10.6% | 16.6% | 0.52 | 12.9% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 18.2% |
| Gold (GLD) | 12.1% | 16.1% | 0.61 | 3.1% |
| Commodities (DBC) | 5.7% | 18.0% | 0.25 | 5.3% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 15.3% |
| Bitcoin (BTCUSD) | 59.0% | 66.2% | 0.99 | 6.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/11/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/11/2026 | 8.0% | 1.9% | 1.7% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 0 | 0 | 0 |
| Median Positive | 8.0% | 1.9% | 1.7% |
| Median Negative | |||
| Max Positive | 8.0% | 1.9% | 1.7% |
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/11/2026 | 8.0% | 1.9% | 1.7% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 0 | 0 | 0 |
| Median Positive | 8.0% | 1.9% | 1.7% |
| Median Negative | |||
| Max Positive | 8.0% | 1.9% | 1.7% |
| Max Negative | |||
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ecor1, Capital, Llc | See Note | Buy | 1122026 | 18.00 | 2,222,222 | 39,999,996 | 78,275,844 | Form | |
| 2 | Vida, Ventures Ii, Llc | See Footnote | Buy | 1122026 | 18.00 | 835,000 | 15,030,000 | 102,092,850 | Form | |
| 3 | Kim, Helen Susan | See Footnote | Buy | 1122026 | 18.00 | 835,000 | 15,030,000 | 102,092,850 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ecor1, Capital, Llc | See Note | Buy | 1122026 | 18.00 | 2,222,222 | 39,999,996 | 78,275,844 | Form | |
| 2 | Vida, Ventures Ii, Llc | See Footnote | Buy | 1122026 | 18.00 | 835,000 | 15,030,000 | 102,092,850 | Form | |
| 3 | Kim, Helen Susan | See Footnote | Buy | 1122026 | 18.00 | 835,000 | 15,030,000 | 102,092,850 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/5/2026